Vivek Thumbigere-Math1, Bryan S Michalowicz2, Pamela J Hughes3, David L Basi4, Michaela L Tsai5, Karen K Swenson6, Laura Rockwell7, Rajaram Gopalakrishnan8. 1. Adjunct Assistant Professor, Division of Periodontology, University of Minnesota School of Dentistry, Minneapolis, MN. 2. Professor, Division of Periodontology, University of Minnesota School of Dentistry, Minneapolis, MN. 3. Associate Professor, Division of Oral and Maxillofacial Surgery, University of Minnesota School of Dentistry, Minneapolis, MN. 4. Adjunct Associate Professor, Boynton Health Service, University of Minnesota, Minneapolis, MN. 5. Oncologist, Oncology Research Department, Park Nicollet Institute, Minneapolis, MN. 6. Oncology Research Director, Oncology Research Department, Park Nicollet Institute, Minneapolis, MN. 7. Research Nurse Clinician, Oncology Research Department, Park Nicollet Institute, Minneapolis, MN. 8. Professor, Division of Oral Pathology, University of Minnesota School of Dentistry, Minneapolis, MN. Electronic address: gopal007@umn.edu.
Abstract
PURPOSE: To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. PATIENTS AND METHODS: Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. RESULTS: The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P < .0001); however, the duration of BP therapy was not significantly different between the groups (P = .23). Overall, there were no significant differences in any of the markers between BRONJ patients and controls (all P values ≥ .16). In a subgroup analysis that matched BRONJ patients and controls according to mean age and number of BP infusions (10 BRONJ patients and 48 controls), log10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P < .001) and C-reactive protein (34 ± 26 mg/L vs 13 ± 8 mg/L, P < .01) levels were significantly higher in BRONJ patients compared with controls. Within BRONJ patients, none of the serum markers were correlated with duration of BP discontinuation. CONCLUSIONS: Levels of bone turnover and endocrine markers in BRONJ patients who discontinue long-term intravenous BP therapy are similar to those in non-BRONJ controls receiving intravenous BP therapy. However, levels of angiogenesis and inflammation markers are higher in BRONJ patients who discontinue long-term intravenous BP therapy. The prolonged skeletal half-life of BPs may suppress bone turnover markers in BRONJ patients for several years after discontinuation of intravenous BP therapy, suggesting an extended effect on bone homeostasis.
PURPOSE: To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. PATIENTS AND METHODS: Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. RESULTS: The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P < .0001); however, the duration of BP therapy was not significantly different between the groups (P = .23). Overall, there were no significant differences in any of the markers between BRONJ patients and controls (all P values ≥ .16). In a subgroup analysis that matched BRONJ patients and controls according to mean age and number of BP infusions (10 BRONJ patients and 48 controls), log10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P < .001) and C-reactive protein (34 ± 26 mg/L vs 13 ± 8 mg/L, P < .01) levels were significantly higher in BRONJ patients compared with controls. Within BRONJ patients, none of the serum markers were correlated with duration of BP discontinuation. CONCLUSIONS: Levels of bone turnover and endocrine markers in BRONJ patients who discontinue long-term intravenous BP therapy are similar to those in non-BRONJ controls receiving intravenous BP therapy. However, levels of angiogenesis and inflammation markers are higher in BRONJ patients who discontinue long-term intravenous BP therapy. The prolonged skeletal half-life of BPs may suppress bone turnover markers in BRONJ patients for several years after discontinuation of intravenous BP therapy, suggesting an extended effect on bone homeostasis.
Authors: Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra Journal: J Oral Maxillofac Surg Date: 2009-05 Impact factor: 1.895
Authors: S Christgau; C Rosenquist; P Alexandersen; N H Bjarnason; P Ravn; C Fledelius; C Herling; P Qvist; C Christiansen Journal: Clin Chem Date: 1998-11 Impact factor: 8.327
Authors: Maguy Chiha; Lauren E Myers; Caroline A Ball; James M Sinacore; Pauline M Camacho Journal: Endocr Pract Date: 2013 Nov-Dec Impact factor: 3.443
Authors: Douglas C Bauer; Ann Schwartz; Lisa Palermo; Jane Cauley; Marc Hochberg; Art Santora; Steven R Cummings; Dennis M Black Journal: JAMA Intern Med Date: 2014-07 Impact factor: 21.873
Authors: P G Arduino; E Menegatti; M Scoletta; C Battaglio; M Mozzati; A Chiecchio; D Berardi; A M Vandone; M Donadio; S Gandolfo; C Scully; R Broccoletti Journal: J Oral Pathol Med Date: 2011-01-20 Impact factor: 4.253
Authors: Peyman Hadji; May Ziller; Tobias Maurer; Michael Autenrieth; Mathias Muth; Amelie Ruebel; Christoph May; Katrin Birkholz; Erhardt Diebel; Jochen Gleissner; Peter Rothe; Juergen E Gschwend Journal: J Bone Oncol Date: 2012-08-10 Impact factor: 4.072
Authors: Ana Laura Soares; Sérgio Simon; Luiz Henrique Gebrim; Afonso Celso P Nazário; Marise Lazaretti-Castro Journal: Support Care Cancer Date: 2019-08-29 Impact factor: 3.603
Authors: Serge Cremers; Matthew T Drake; F Hal Ebetino; John P Bilezikian; R Graham G Russell Journal: Br J Clin Pharmacol Date: 2019-02-28 Impact factor: 4.335
Authors: Erofili Papadopoulou; Ourania Nicolatou-Galitis; Ioannis Papassotiriou; Helena Linardou; Aikaterini Karagianni; Konstantinos Tsixlakis; Anthi Tarampikou; Kelly Michalakakou; Emmanouil Vardas; Dimitrios Bafaloukos Journal: Support Care Cancer Date: 2019-04-17 Impact factor: 3.603
Authors: Martin Salgueiro; Michael Stribos; Li Fang Zhang; Mark Stevens; Mohamed E Awad; Mohammed Elsalanty Journal: EPMA J Date: 2019-01-24 Impact factor: 6.543
Authors: Andreas Max Pabst; Maximilian Krüger; Sebastian Blatt; Thomas Ziebart; Roman Rahimi-Nedjat; Elisabeth Goetze; Christian Walter Journal: Dent J (Basel) Date: 2016-12-26